Reviewing Applied Genetic Technologies Corporation (AGTC) and TOCAGEN INC (TOCA)
Applied Genetic Technologies Corporation (NASDAQ: AGTC) and TOCAGEN INC (NASDAQ:TOCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
This table compares Applied Genetic Technologies Corporation and TOCAGEN INC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Applied Genetic Technologies Corporation||4.28%||1.45%||1.05%|
Institutional and Insider Ownership
54.6% of Applied Genetic Technologies Corporation shares are owned by institutional investors. Comparatively, 37.9% of TOCAGEN INC shares are owned by institutional investors. 5.6% of Applied Genetic Technologies Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Applied Genetic Technologies Corporation and TOCAGEN INC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Applied Genetic Technologies Corporation||0||1||6||0||2.86|
Applied Genetic Technologies Corporation presently has a consensus target price of $11.71, indicating a potential upside of 244.54%. TOCAGEN INC has a consensus target price of $23.67, indicating a potential upside of 119.95%. Given Applied Genetic Technologies Corporation’s higher probable upside, equities analysts clearly believe Applied Genetic Technologies Corporation is more favorable than TOCAGEN INC.
Earnings and Valuation
This table compares Applied Genetic Technologies Corporation and TOCAGEN INC’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Applied Genetic Technologies Corporation||$39.47 million||1.56||$400,000.00||$0.08||42.51|
|TOCAGEN INC||$40,000.00||5,328.89||-$33.47 million||N/A||N/A|
Applied Genetic Technologies Corporation has higher revenue and earnings than TOCAGEN INC.
Applied Genetic Technologies Corporation beats TOCAGEN INC on 9 of the 11 factors compared between the two stocks.
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
About TOCAGEN INC
Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.